Deals this week: Heat Biologics, Celsion Corporation, Cambridge Isotope Laboratories

13 October 2016 (Last Updated October 13th, 2016 18:30)

Heat Biologics and Adaptive Biotechnologies Corporation have entered an agreement to further develop novel immunotherapies.

Heat Biologics and Adaptive Biotechnologies Corporation have entered an agreement to further develop novel immunotherapies.

Pursuant to the agreement, Heat Biologics’ ImPACT and ComPACT-based immunotherapies will be analysed and characterised using Adaptive Biotechnologies’ ImmunoSEQ, an immune profiling assay.

The agreement enables the two partners to identify significant biomarkers to further develop immunotherapies.

Celsion Corporation and Children’s Research Institute have entered a partnership to develop new treatments for solid tumours in children and young adults.

"Celsion Corporation and Children’s Research Institute have entered a partnership to develop new treatments for solid tumours in children and young adults."

Under the agreement, the two partners will study the use of ThermoDox in combination with high-intensity focused ultrasound in a Phase I clinical study to treat the relapsed or refractory solid tumours.

The Phase I clinical study will be partly funded by the National institutes of Health.

Cambridge Isotope Laboratories and IROA Technologies have entered an agreement to develop and distribute the latter’s Biochemical Quantitation kits worldwide.

The two partners will develop the kits for metabolic profiling for cell populations and biological samples to overcome the analytical challenges of metabolic analysis.

Accelerated Pharma has announced initial public offering (IPO) of its 1.8 million common stock shares to raise gross proceeds of up to $18.9 million.

Rodman & Renshaw and Maxim Group are acting as joint book runners, while Ellen Grossman & Schole is acting as the legal advisor to the offering.

The company plans to use the funds to advance its Phase II clinical trial for Picoplatin and also to increase the working capital and for other general corporate purposes.

Eris Lifesciences plans to issue its shares in initial public offering (IPO) through ChrysCapital Management Company.

The company expects to raise $300 million from the offering.

Axis Capital, Credit Suisse Securities (India) and Citigroup Global Markets India are the financial advisors for the offering.